Literature DB >> 10948114

Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins.

W G Hu1, J Chen, J F Battey, X X Gu.   

Abstract

Moraxella catarrhalis strain 25238 detoxified lipooligosaccharide (dLOS)-protein conjugates induced a significant rise of bactericidal anti-LOS antibodies in animals. This study reports the effect of active or passive immunization with the conjugates or their antiserum on pulmonary clearance of M. catarrhalis in an aerosol challenge mouse model. Mice were injected subcutaneously with dLOS-tetanus toxoid (dLOS-TT), dLOS-high-molecular-weight proteins (dLOS-HMP) from nontypeable Haemophilus influenzae (NTHi), or nonconjugated materials in Ribi adjuvant and then challenged with M. catarrhalis strain 25238 or O35E or NTHi strain 12. Immunization with dLOS-TT or dLOS-HMP generated a significant rise of serum anti-LOS immunoglobulin G and 68% and 35 to 41% reductions of bacteria in lungs compared with the control (P<0.01) following challenge with homologous strain 25238 and heterologous strain O35E, respectively. Serum anti-LOS antibody levels correlated with its bactericidal titers against M. catarrhalis and bacterial CFU in lungs. Additionally, immunization with dLOS-HMP generated a 54% reduction of NTHi strain 12 compared with the control (P<0.01). Passive immunization with a rabbit antiserum against dLOS-TT conferred a significant reduction of strain 25238 CFU in lungs in a dose- and time-dependent pattern compared with preimmune serum-treated mice. Kinetic examination of lung tissue sections demonstrated that antiserum-treated mice initiated and offset inflammatory responses more rapidly than preimmune serum-treated mice. These data indicate that LOS antibodies (whether active or passive) play a major role in the enhancement of pulmonary clearance of different test strains of M. catarrhalis in mice. In addition, dLOS-HMP is a potential candidate for a bivalent vaccine against M. catarrhalis and NTHi infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948114      PMCID: PMC101715          DOI: 10.1128/IAI.68.9.4980-4985.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A B Brueggemann; G Pierce; T Hogan; H P Holley; A Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

2.  Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins.

Authors:  X X Gu; C M Tsai; T Ueyama; S J Barenkamp; J B Robbins; D J Lim
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

Review 3.  Neonatal meningitis due to Moraxella catarrhalis and review of the literature.

Authors:  A Daoud; F Abuekteish; H Masaadeh
Journal:  Ann Trop Paediatr       Date:  1996-09

4.  Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization.

Authors:  D Chen; J C McMichael; K R VanDerMeid; D Hahn; T Mininni; J Cowell; J Eldridge
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

Review 5.  Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response.

Authors:  T F Murphy
Journal:  Microbiol Rev       Date:  1996-06

6.  Lack of serotype-specific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection.

Authors:  M Rahman; T Holme; I Jönsson; A Krook
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

7.  Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media.

Authors:  H Faden; Y Harabuchi; J J Hong
Journal:  J Infect Dis       Date:  1994-06       Impact factor: 5.226

8.  Immune response to Moraxella catarrhalis in children with otitis media: opsonophagocytosis with antigen-coated latex beads.

Authors:  H Faden; J J Hong; N Pahade
Journal:  Ann Otol Rhinol Laryngol       Date:  1994-07       Impact factor: 1.547

Review 9.  Spectrum and significance of bacteremia due to Moraxella catarrhalis.

Authors:  J P Ioannidis; M Worthington; J K Griffiths; D R Snydman
Journal:  Clin Infect Dis       Date:  1995-08       Impact factor: 9.079

Review 10.  Moraxella (Branhamella) catarrhalis bacteremia in children. A report of two patients and review of the literature.

Authors:  G A Meyer; T R Shope; N J Waecker; F H Lanningham
Journal:  Clin Pediatr (Phila)       Date:  1995-03       Impact factor: 1.168

View more
  17 in total

1.  Identification of two late acyltransferase genes responsible for lipid A biosynthesis in Moraxella catarrhalis.

Authors:  Song Gao; Daxin Peng; Wenhong Zhang; Artur Muszyński; Russell W Carlson; Xin-Xing Gu
Journal:  FEBS J       Date:  2008-09-13       Impact factor: 5.542

2.  Bactericidal monoclonal antibody against Moraxella catarrhalis lipooligosaccharide cross-reacts with Haemophilus Spp.

Authors:  Raina T Gergova; Ianko D Iankov; Iana H Haralambieva; Ivan G Mitov
Journal:  Curr Microbiol       Date:  2007-01-05       Impact factor: 2.188

3.  Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

4.  Characterization of a cluster of three glycosyltransferase enzymes essential for Moraxella catarrhalis lipooligosaccharide assembly.

Authors:  Katie J Edwards; Simon Allen; Bradford W Gibson; Anthony A Campagnari
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

Review 5.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

7.  Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine.

Authors:  Xinan Jiao; Takashi Hirano; Yingchun Hou; Xin-Xing Gu
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

Review 8.  A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

9.  Late acyltransferase genes lpxX and lpxL jointly contribute to the biological activities of Moraxella catarrhalis.

Authors:  Song Gao; Dabin Ren; Daxin Peng; Wenhong Zhang; Artur Muszyński; Russell W Carlson; Xin-Xing Gu
Journal:  J Med Microbiol       Date:  2013-03-08       Impact factor: 2.472

10.  Use of Moraxella catarrhalis lipooligosaccharide mutants to identify specific oligosaccharide epitopes recognized by human serum antibodies.

Authors:  Johanna M Schwingel; Katie J Edwards; Andrew D Cox; Hussein Masoud; James C Richards; Frank St Michael; Carmen D Tekwe; Sanjay Sethi; Timothy F Murphy; Anthony A Campagnari
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.